Patent Opposition Proceedings in Biotechnology

Introduction

Patent opposition proceedings in biotechnology are legal mechanisms through which interested parties or members of the public can challenge a patent application or a granted patent on specified statutory grounds. Biotechnology patents may cover genetically engineered organisms, microorganisms, biological processes, pharmaceutical formulations, vaccines and genetic technologies.

These proceedings are particularly important because an improperly granted biotechnology patent may restrict scientific research, pharmaceutical competition and access to essential medicines. In India, opposition proceedings are primarily governed by Sections 25(1) and 25(2) of the Patents Act, 1970.

Government of India

+1

1. Types of Patent Opposition

Pre-grant opposition — Section 25(1): Any person may submit a written representation against a published patent application before the patent is granted.

Post-grant opposition — Section 25(2): A person interested may oppose a granted patent within one year from the date of publication of the grant.

Both procedures allow challenges on prescribed grounds, including lack of novelty, lack of inventive step, wrongful obtaining, insufficient disclosure and certain exclusions from patentability.

Government of India

+1

2. Grounds for Opposing Biotechnology Patents

Lack of novelty: An invention may be challenged if its essential features were already disclosed in scientific publications, earlier patent documents or other qualifying prior art.

Lack of inventive step: A patent may be opposed if the claimed biotechnology invention would have been obvious to a person skilled in the relevant scientific field.

Insufficient disclosure: The specification must describe the invention sufficiently and clearly, including how it can be performed. This is particularly important where the invention involves complex biological materials or experimental procedures.

Non-patentable subject matter: Section 3(j) excludes plants and animals, in whole or in part, other than microorganisms, including seeds, varieties and essentially biological processes for producing or propagating plants and animals.

Improper disclosure of biological origin: Section 25 permits opposition where the complete specification fails to disclose, or wrongly mentions, the source and geographical origin of biological material used in the invention.

Government of India

+1

3. Important Case Laws

A. Novartis AG v. Union of India, (2013) 6 SCC 1

The Supreme Court considered whether Novartis could obtain a patent for the beta crystalline form of imatinib mesylate, a pharmaceutical substance used in cancer treatment. The dispute arose after opposition to the patent application and concerned the requirements of novelty, inventive step and Section 3(d) of the Patents Act.

The Court refused the patent because the claimed substance did not satisfy the enhanced therapeutic-efficacy requirement under Section 3(d).

Legal principle: Biotechnology and pharmaceutical inventions must satisfy statutory patentability requirements. Patent opposition can help prevent patents from being granted over subject matter that does not qualify for protection.

cdn.patentoppositions.org

+1

B. Cipla Ltd. v. Union of India, decided 27 November 2012

The Supreme Court considered a patent opposition dispute involving the revocation of a pharmaceutical patent and the procedure followed by the Controller. The central issue was whether the parties had been provided with the Opposition Board’s recommendation.

The Court remitted the matter for fresh consideration in accordance with law, emphasising the importance of procedural fairness.

Legal principle: Patent opposition proceedings must comply with natural justice. Parties must receive the material required to make an effective response to the decision-making process.

Indian Kanoon

+1

C. Novartis AG v. Natco Pharma Limited, Delhi High Court, 9 January 2024

The Delhi High Court examined issues concerning post-grant patent opposition under Section 25(2), including the statutory grounds available to opponents and the framework governing opposition proceedings.

The judgment discusses the distinction between pre-grant opposition, which may be initiated by any person, and post-grant opposition, which requires the opponent to be a person interested.

Legal principle: Patent opposition must be pursued through the prescribed statutory procedure and on legally recognised grounds.

Indian Kanoon

+1

4. Procedure and Legal Consequences

Under the applicable Patent Rules, an opponent submits a representation or notice supported by evidence. The patent applicant or patentee receives an opportunity to respond, and the Controller considers the relevant submissions and evidence. In post-grant opposition, an Opposition Board examines the matter and makes recommendations before the Controller issues an appropriate order.

Depending on the applicable procedure and findings, the patent application may be refused, or a granted patent may be maintained, amended or revoked. An opposition is not automatically successful merely because a challenge has been filed.

Conclusion

Patent opposition proceedings are an important safeguard in biotechnology law. Sections 25 and 3(j) of the Patents Act, 1970, help ensure that only qualifying inventions receive patent protection. The Novartis decision illustrates the importance of substantive patentability requirements, while Cipla Ltd. v. Union of India emphasises procedural fairness. Effective opposition proceedings protect genuine innovation while limiting unjustified monopolies over biological materials, scientific knowledge and pharmaceutical inventions.